Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D

Tyrosine kinase inhibitor is an effective chemo-therapeutic drug against tumors with deregulated EGFR pathway. Recently, a genetic variant rs10251977 (G>A) in exon 20 of EGFR reported to act as a prognostic marker for HNSCC. Genotyping of this polymorphism in oral cancer patients showed a similar...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-04, Vol.11 (1), p.8808-8808, Article 8808
Main Authors: Dhamodharan, Shankar, Rose, Mathew Maria, Chakkarappan, Sundaram Reddy, Umadharshini, Karuppiah Vijayamuthuramalingam, Arulmurugan, Ramalingam, Subbiah, Shanmugam, Inoue, Ituro, Munirajan, Arasambattu Kannan
Format: Article
Language:English
Subjects:
631/208
631/337
631/67
692/4028
Alternative splicing
Antisense Elements (Genetics) - genetics
Binding sites
Cell Line, Tumor
Enzyme inhibitors
Epidermal growth factor receptors
ErbB Receptors - genetics
Genetic diversity
Genetic variance
Genetic Variation
Genotype
Genotyping
Humanities and Social Sciences
Humans
Isoforms
Kinases
Mouth Neoplasms - genetics
multidisciplinary
Oral cancer
Polymorphism
Protein Isoforms - genetics
Protein-tyrosine kinase
Science
Science (multidisciplinary)
Squamous cell carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tyrosine kinase inhibitor is an effective chemo-therapeutic drug against tumors with deregulated EGFR pathway. Recently, a genetic variant rs10251977 (G>A) in exon 20 of EGFR reported to act as a prognostic marker for HNSCC. Genotyping of this polymorphism in oral cancer patients showed a similar frequency in cases and controls. EGFR-AS1 expressed significantly high level in tumors and EGFR-A isoform expression showed significant positive correlation (r = 0.6464, p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-88161-3